Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers Pricing

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

argenx Jobs | Formulate

Jobs
argenx

argenx Jobs

Belgium - Zwijnaarde

Biotechnology

argenx is a life sciences company focused on Antibody therapies.

6 open positions at argenx

View Full Profile

Filters:Neurology ×

Territory Business Manager - Denver, CO

argenx

Posted 2d ago

Denver

$140K - $193K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Neurology

H-1B · 1 FY23

Executive Director, US HCP Marketing - CIDP Indication Lead

argenx

Posted 2w ago

Remote

$260K - $357K

Full-time

Senior Director, Portfolio Marketing Community Lead

argenx

Posted 3w ago

Remote

$236K - $325K

Full-time

Senior Director, Emerging Science and Pipeline Marketing Community Lead

argenx

Posted 3w ago

Remote

$236K - $325K

Full-time

Business Leader, Southwest (Las Vegas Metro)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Business Leader, Northeast (New England)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Company Overview

Active Jobs

84

Pipeline Programs

88

Drug Products

2

Clinical Trials

98

View Full Company Profile

Therapeutic Areas

Neurology Immunology Oncology

Links

Company Website Careers Page

Related drug: VYVGART HYTRULO

Related drug: VYVGART

Related drug: HYDASE

Condition in scope: Chronic Inflammatory Demyelinating Polyneuropathy Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteCommercialNeurologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteCommercialNeurologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteCommercialNeurologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

NeurologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

NeurologyMID

H-1B · 1 FY23